Sanibel Captiva Trust Company Inc. Reduces Position in Kenvue Inc. (NYSE:KVUE)

Sanibel Captiva Trust Company Inc. lessened its stake in Kenvue Inc. (NYSE:KVUE) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 36,406 shares of the company’s stock after selling 2,635 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Kenvue were worth $777,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of KVUE. FMR LLC increased its stake in Kenvue by 2.3% in the 3rd quarter. FMR LLC now owns 137,915,493 shares of the company’s stock worth $3,189,985,000 after buying an additional 3,075,019 shares in the last quarter. State Street Corp raised its stake in Kenvue by 16.8% during the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after purchasing an additional 18,283,473 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock worth $2,011,832,000 after purchasing an additional 7,115,374 shares in the last quarter. Geode Capital Management LLC boosted its stake in Kenvue by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock worth $1,029,810,000 after purchasing an additional 399,846 shares during the period. Finally, Harris Associates L P grew its holdings in Kenvue by 7.5% during the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock valued at $727,658,000 after buying an additional 2,186,114 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE stock opened at $21.11 on Friday. The stock has a market cap of $40.46 billion, a PE ratio of 38.37, a P/E/G ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a 50-day moving average price of $22.42 and a 200 day moving average price of $21.69. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the previous year, the business earned $0.31 earnings per share. The company’s revenue for the quarter was down .4% compared to the same quarter last year. Equities research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.89%. Kenvue’s dividend payout ratio (DPR) is 149.09%.

Analysts Set New Price Targets

Several research firms have recently commented on KVUE. Barclays lowered their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. UBS Group cut their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research report on Thursday. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and cut their price target for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Finally, Citigroup decreased their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.